European journal of heart failure · 2026
Longitudinal proteomic organ-specific aging in heart failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qu Kaiyong, Diez Benavente Ernest, Hatip Ünlü Ezgi, van Ommen Anne-Mar L N, Handoko M Louis, Teske Arco J, Cramer Maarten Jan, Asselbergs Folkert W, Rutten Frans H, Boersma Eric, den Ruijter Hester M, Onland-Moret N Charlotte, Kardys Isabella, Dal Canto Elisa
Аннотация
BACKGROUND: Heart failure (HF) is a systemic syndrome affecting multiple organs. Organ age gaps (OAGs), quantifying organ-level aging from plasma proteomics, are linked to organ-specific disease including HF but have been studied exclusively cross-sectionally. We examined how organ-specific aging evolves within individuals over the course of HF and whether it carries prognostic information beyond established HF markers.
METHODS: We studied two complementary cohorts with repeated plasma proteomic profiling: 557 individuals including those at risk for HF, pre-HF, and newly diagnosed HF (HELPFul, mainly HFpEF)and 382 patients with established HF (Bio-SHiFT, all LVEF < 50%). OAGs for five organs plus a conventional clock were z-scored. Within each cohort, we modelled longitudinal OAG trajectories using linear mixed-effects models, and, in Bio-SHiFT, related OAGs to the primary endpoint using Cox models with progressive adjustment up to NT-proBNP and troponin T.
RESULTS: Baseline OAGs differed across HF severity in both cohorts. Longitudinally, 50 HELPFul individuals with LVDD showed increasing artery and immune OAGs over 4.6 years. In Bio-SHiFT, event-free patients had stable trajectories, whereas those with adverse events showed sharply accelerating multi-organ aging over 2.1 years (immune β = 0.36 z-score per year, 95% CI 0.26 to 0.47; heart β = 0.29, 95% CI 0.17 to 0.40). Higher OAGs predicted the primary endpoint, and the kidney, lung, and immune OAGs remained prognostic after full adjustment including NT-proBNP and troponin T.
CONCLUSION: In this exploratory study, multi-organ aging accelerated before adverse events, and the kidney, lung, and immune OAGs predicted outcome independently of conventional severity markers, supporting a dynamic, organ-level view of HF risk that warrants confirmation in larger cohorts.
METHODS: We studied two complementary cohorts with repeated plasma proteomic profiling: 557 individuals including those at risk for HF, pre-HF, and newly diagnosed HF (HELPFul, mainly HFpEF)and 382 patients with established HF (Bio-SHiFT, all LVEF < 50%). OAGs for five organs plus a conventional clock were z-scored. Within each cohort, we modelled longitudinal OAG trajectories using linear mixed-effects models, and, in Bio-SHiFT, related OAGs to the primary endpoint using Cox models with progressive adjustment up to NT-proBNP and troponin T.
RESULTS: Baseline OAGs differed across HF severity in both cohorts. Longitudinally, 50 HELPFul individuals with LVDD showed increasing artery and immune OAGs over 4.6 years. In Bio-SHiFT, event-free patients had stable trajectories, whereas those with adverse events showed sharply accelerating multi-organ aging over 2.1 years (immune β = 0.36 z-score per year, 95% CI 0.26 to 0.47; heart β = 0.29, 95% CI 0.17 to 0.40). Higher OAGs predicted the primary endpoint, and the kidney, lung, and immune OAGs remained prognostic after full adjustment including NT-proBNP and troponin T.
CONCLUSION: In this exploratory study, multi-organ aging accelerated before adverse events, and the kidney, lung, and immune OAGs predicted outcome independently of conventional severity markers, supporting a dynamic, organ-level view of HF risk that warrants confirmation in larger cohorts.